A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Pyrotinib|DRUG: Treatment of physician's choice|DRUG: vinorelbine
Sponsor: Sun Yat-sen University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.